Treatment of acromegaly with somatostatin analogues (SS-a) results in reduction of circulating GH and insulin-like growth factor-I (IGF-I), and also significant tumor size reduction in a substantial proportion of patients [2, 3]. Here, GH1 is linked to acromegaly.